Stock Data
$7.19 (2.21%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
DIAGNOSTICS & RESEARCH
Natera Inc is a pioneering diagnostics company that offers a wide range of molecular testing services globally. Its innovative portfolio includes Panorama, a non-invasive prenatal test for chromosomal abnormalities, and Horizon, a carrier screening test. Natera also provides Vistara, Spectrum, Anora, Empower, and a non-invasive prenatal paternity product. Additionally, it offers Signatera for cancer recurrence monitoring, Altera for genomic profiling, Prospera for transplant rejection assessment, and Renasight for kidney gene panel testing. Natera enhances its offerings through partnerships and a cloud-based software, Constellation, facilitating access to its advanced algorithms and bioinformatics. Founded in 2003, Natera is headquartered in Austin, Texas.
Management lifted full-year revenue guidance $100 million at the midpoint to $2.85 billion to $2.91 billion after oncology test volumes jumped 57.2% year over year. Signatera's FDA companion diagnostic approval in bladder cancer, plus Japanese and EU clearances, widens the market behind that raise. FIND-CRC enrollment wraps in Q3.
12 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
